33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors
    Meeting Abstract

    Drilon, A.; Besse, B.; Camidge, D. R.; Ou, S. H. I.; Gadgeel, S. M.; Johnson, M. L.; Calles, A.; de Miguel, M. J.; Spira, A. I.; Felip, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • A radiohapten capture system for CAR T cells that tracks them in vivo and improves efficacy
    Meeting Abstract

    Kurtz, K.; Eibler, L.; Dacek, M.; Carter, L.; Cheal, S.; Veach, D.; Qureshy, S.; Han, J.; Reynaud, E.; Verma, S.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G.; Vogl, A.; Schumacher, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
    Meeting Abstract

    Zain, D. R.; Iyer, S. P.; Sica, R. A.; Ho, P. J.; Hu, B.; Prica, A.; Weng, W. K.; Kim, Y. H.; Khodadoust, M. S.; Palomba, M. L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Cho, B. C.; Lin, J.; Camidge, D. R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K. H.; Kim, S. W.; Kao, S.; Diadziuskzko, R.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1
    Meeting Abstract

    Hu, J.; Villano, A.; O'Connor, R.; Rozenberg, Y.; Venkatesh, A.; Gounder, M.; Socci, N.; Singer, S.; Hameed, M.; Crago, A. M.
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Enrollment of pediatric and adolescent patients with MAGE-A4+advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel ("afami-cel" [formerly ADP-A2M4])
    Meeting Abstract

    Lunt, C.; D'Angelo, S. P.; Razak, A. R. A.; Wagner, M. J.; Van Tine, B. A.; Ganjoo, K.; Blay, J. Y.; Araujo, D. M.; Agulnik, M.; Glod, J. W.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Predictors of outcomes in hematopoietic cell transplantation for fanconi anemia: A multicenter analysis
    Meeting Abstract

    Cancio, M.; Troullioud, A.; Elizabeth, K.; de Witte, M.; Smiers, F.; Bresters, D.; Boelens, J. J.; Bierings, M.; Smetsers, S.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • Matched sibling donor transplant with reduced intensity conditioning has excellent results in pediatric bone marrow failure syndromes
    Meeting Abstract

    Oved, J.; Elgarten, C.; Levy, E.; Monos, D.; Wang, Y.; Barrett, D.; Grupp, S.; Bunin, N.; Olson, T.
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • Excellent 3-year survival in recipients of mismatched unrelated donor transplants using post-transplant cyclophosphamide: Longer term outcomes of a national marrow donor program-sponsored prospective clinical trial
    Meeting Abstract

    Shaw, B.; Jimenez-Jimenez, A. M.; Burns, L.; Logan, B.; Khimani, F.; Shaffer, B.; Shah, N.; Mussetter, A.; Tang, X. Y.; McCarty, J.; more...
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save